Skip to content
2000
Volume 32, Issue 18
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Immunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review. Solo nivolumab and combo nivolumab-ipilimumab show higher responses compared to solo ipilimumab or chemotherapy. BRAF and programmed death-ligand 1 (PD-L1) expression states are seemingly not reliable biomarkers of response to ICI therapy in melanoma. Solo ipilimumab and particularly a combination of nivolumab-ipilimumab show higher adverse events (AEs) compared with solo nivolumab or chemotherapy. Besides, ICI therapy is safer in mucosal melanoma, but its efficacy is higher in the cutaneous subtype. Patients receiving combination regimens who are experiencing serious AEs can discontinue such regimens until recovery and still maintain clinical benefits. To conclude, combo nivolumab-ipilimumab represents more therapeutic advantages compared with solo nivolumab or ipilimumab, but the rate of AEs is higher for combination regimens. Resistance to combo nivolumab-ipilimumab demands the application of novel approaches to go with ICIs in melanoma immunotherapy. Immunogenic agents, alternative immune checkpoints, vaccination, oncolytic viruses, extracellular vesicles (EVs) and fecal microbiome transplantation (FMT) are novel strategies in patients developing ICI resistance.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673283943240227104122
2024-03-06
2025-10-14

  • From This Site

    /content/journals/cmc/10.2174/0109298673283943240227104122
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. YamazakiN. KiyoharaY. UharaH. UeharaJ. FujisawaY. TakenouchiT. OtsukaM. UchiH. IhnH. HatsumichiM. MinamiH. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.Cancer Sci.201911061995200310.1111/cas.1401530959557
     [Google Scholar]
  2. ForschnerA. BattkeF. HadaschikD. SchulzeM. WeißgraeberS. HanC.T. KoppM. FrickM. KlumppB. TietzeN. AmaralT. MartusP. SinnbergT. EigentlerT. KeimU. GarbeC. DöckerD. BiskupS. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma–results of a prospective biomarker study.J. Immunother. Cancer20197118010.1186/s40425‑019‑0659‑031300034
     [Google Scholar]
  3. MortezaeeK. MajidpoorJ. Extracellular vesicle-based checkpoint regulation and immune state in cancer.Med. Oncol.2022391222510.1007/s12032‑022‑01837‑236175741
     [Google Scholar]
  4. MortezaeeK. MajidpoorJ. Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1.Biomed. Pharmacother.202316311482410.1016/j.biopha.2023.11482437141735
     [Google Scholar]
  5. ZimmerL. LivingstoneE. HasselJ.C. FluckM. EigentlerT. LoquaiC. HaferkampS. GutzmerR. MeierF. MohrP. HauschildA. SchillingB. MenzerC. KiekerF. DippelE. RöschA. SimonJ.C. ConradB. KörnerS. Windemuth-KieselbachC. SchwarzL. GarbeC. BeckerJ.C. SchadendorfD. BerkingC. HerbstR.A. MartensU.M. SellS. StadlerR. TerheydenP. UtikalJ. Dermatologic Cooperative Oncology Group Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial.Lancet2020395102361558156810.1016/S0140‑6736(20)30417‑732416781
     [Google Scholar]
  6. AsciertoP.A. Del VecchioM. MandaláM. GogasH. AranceA.M. DalleS. CoweyC.L. SchenkerM. GrobJ.J. Chiarion-SileniV. Márquez-RodasI. ButlerM.O. MaioM. MiddletonM.R. de la Cruz-MerinoL. ArenbergerP. AtkinsonV. HillA. FecherL.A. MillwardM. KhushalaniN.I. QueiroloP. LoboM. de PrilV. LoffredoJ. LarkinJ. WeberJ. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.Lancet Oncol.202021111465147710.1016/S1470‑2045(20)30494‑032961119
     [Google Scholar]
  7. CharehjooA. MajidpoorJ. MortezaeeK. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.Int. Immunopharmacol.202311811003210.1016/j.intimp.2023.11003236933494
     [Google Scholar]
  8. KoopmansI. Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade.J Invest Dermatol20191391123432351
     [Google Scholar]
  9. MartinezM. KimS. St JeanN. O’BrienS. LianL. SunJ. VeronaR.I. MoonE. Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer.OncoImmunology2021101187360710.1080/2162402X.2021.187360733537176
     [Google Scholar]
  10. HemstockM. AmadiA. KupasK. RoskellN. KotapatiS. GoodenK. MiddletonM.R. SchadendorfD. Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.Eur. J. Cancer202013217618610.1016/j.ejca.2020.03.01132380428
     [Google Scholar]
  11. D’AngeloS.P. LarkinJ. SosmanJ.A. LebbéC. BradyB. NeynsB. SchmidtH. HasselJ.C. HodiF.S. LoriganP. SavageK.J. MillerW.H.Jr MohrP. Marquez-RodasI. CharlesJ. KaatzM. SznolM. WeberJ.S. ShoushtariA.N. RuisiM. JiangJ. WolchokJ.D. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis.J. Clin. Oncol.201735222623510.1200/JCO.2016.67.925828056206
     [Google Scholar]
  12. NomuraM. OzeI. MasuishiT. YokotaT. SatakeH. IwasawaS. KatoK. AndohM. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.Int. J. Clin. Oncol.202025597297710.1007/s10147‑020‑01618‑931938955
     [Google Scholar]
  13. TosiA. CappellessoR. Dei TosA.P. RossiV. AlibertiC. PigozzoJ. FabozziA. SbaragliaM. BlandamuraS. Del BiancoP. Chiarion-SileniV. RosatoA. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.J. Exp. Clin. Cancer Res.202140115410.1186/s13046‑021‑01947‑133947438
     [Google Scholar]
  14. NewellF. WilmottJ.S. JohanssonP.A. NonesK. AddalaV. MukhopadhyayP. BroitN. AmatoC.M. Van GulickR. KazakoffS.H. PatchA.M. KoufariotisL.T. LakisV. LeonardC. WoodS. HolmesO. XuQ. LewisK. MedinaT. GonzalezR. SawR.P.M. SpillaneA.J. StretchJ.R. RawsonR.V. FergusonP.M. DoddsT.J. ThompsonJ.F. LongG.V. LevesqueM.P. RobinsonW.A. PearsonJ.V. MannG.J. ScolyerR.A. WaddellN. HaywardN.K. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.Nat. Commun.2020111525910.1038/s41467‑020‑18988‑333067454
     [Google Scholar]
  15. PapageorgiouC. Melanoma: Staging and follow-up. Dermatol. Pract. Concept.202111Suppl 1e2021162S10.5826/dpc.11S1a162S
     [Google Scholar]
  16. MohrP. EggermontA.M.M. HauschildA. BuzaidA. Staging of cutaneous melanoma.Ann. Oncol.200920Suppl 6vi14vi2110.1093/annonc/mdp25619617293
     [Google Scholar]
  17. BalchC.M. SoongS.J. AtkinsM.B. BuzaidA.C. CascinelliN. CoitD.G. FlemingI.D. GershenwaldJ.E. HoughtonA.Jr KirkwoodJ.M. McMastersK.M. MihmM.F. MortonD.L. ReintgenD.S. RossM.I. SoberA. ThompsonJ.A. ThompsonJ.F. An evidence-based staging system for cutaneous melanoma.CA Cancer J. Clin.200454313114910.3322/canjclin.54.3.13115195788
     [Google Scholar]
  18. AmariaR.N. ReddyS.M. TawbiH.A. DaviesM.A. RossM.I. GlitzaI.C. CormierJ.N. LewisC. HwuW.J. HannaE. DiabA. WongM.K. RoyalR. GrossN. WeberR. LaiS.Y. EhlersR. BlandoJ. MiltonD.R. WoodmanS. KageyamaR. WellsD.K. HwuP. PatelS.P. LucciA. HesselA. LeeJ.E. GershenwaldJ. SimpsonL. BurtonE.M. PosadaL. HayduL. WangL. ZhangS. LazarA.J. HudgensC.W. GopalakrishnanV. ReubenA. AndrewsM.C. SpencerC.N. PrietoV. SharmaP. AllisonJ. TetzlaffM.T. WargoJ.A. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.Nat. Med.201824111649165410.1038/s41591‑018‑0197‑130297909
     [Google Scholar]
  19. SchadendorfD. HodiF.S. RobertC. WeberJ.S. MargolinK. HamidO. PattD. ChenT.T. BermanD.M. WolchokJ.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.J. Clin. Oncol.201533171889189410.1200/JCO.2014.56.273625667295
     [Google Scholar]
  20. Castaneda, M.; den Hollander, P.; Kuburich, N.A.; Rosen, J.M.; Mani, S.A. Mechanisms of cancer metastasis. Seminars in cancer biology., 2022, 87, 17-3110.1016/j.semcancer.2022.10.00636354098
  21. JiangG. LiR.H. SunC. LiuY.Q. ZhengJ.N. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: A meta-analysis.PLoS One2014912011192010.1371/journal.pone.011192025502446
     [Google Scholar]
  22. PrietoP.A. YangJ.C. SherryR.M. HughesM.S. KammulaU.S. WhiteD.E. LevyC.L. RosenbergS.A. PhanG.Q. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma.Clin. Cancer Res.20121872039204710.1158/1078‑0432.CCR‑11‑182322271879
     [Google Scholar]
  23. CarlinoM.S. SandhuS. Safety and efficacy implications of discontinuing combination ipilimumab and nivolumab in advanced melanoma.J. Clin. Oncol.201735343792379310.1200/JCO.2017.75.205529048973
     [Google Scholar]
  24. EggermontA.M.M. Chiarion-SileniV. GrobJ.J. DummerR. WolchokJ.D. SchmidtH. HamidO. RobertC. AsciertoP.A. RichardsJ.M. LebbéC. FerraresiV. SmylieM. WeberJ.S. MaioM. BastholtL. MortierL. ThomasL. TahirS. HauschildA. HasselJ.C. HodiF.S. TaittC. de PrilV. de SchaetzenG. SuciuS. TestoriA. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.N. Engl. J. Med.2016375191845185510.1056/NEJMoa161129927717298
     [Google Scholar]
  25. CallahanM.K. KlugerH. PostowM.A. SegalN.H. LesokhinA. AtkinsM.B. KirkwoodJ.M. KrishnanS. BhoreR. HorakC. WolchokJ.D. SznolM. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study.J. Clin. Oncol.201836439139810.1200/JCO.2017.72.285029040030
     [Google Scholar]
  26. WolchokJ.D. Chiarion-SileniV. GonzalezR. RutkowskiP. GrobJ.J. CoweyC.L. LaoC.D. WagstaffJ. SchadendorfD. FerrucciP.F. SmylieM. DummerR. HillA. HoggD. HaanenJ. CarlinoM.S. BechterO. MaioM. Marquez-RodasI. GuidoboniM. McArthurG. LebbéC. AsciertoP.A. LongG.V. CebonJ. SosmanJ. PostowM.A. CallahanM.K. WalkerD. RollinL. BhoreR. HodiF.S. LarkinJ. Overall survival with combined nivolumab and ipilimumab in advanced melanoma.N. Engl. J. Med.2017377141345135610.1056/NEJMoa170968428889792
     [Google Scholar]
  27. LarkinJ. Chiarion-SileniV. GonzalezR. GrobJ.J. RutkowskiP. LaoC.D. CoweyC.L. SchadendorfD. WagstaffJ. DummerR. FerrucciP.F. SmylieM. HoggD. HillA. Márquez-RodasI. HaanenJ. GuidoboniM. MaioM. SchöffskiP. CarlinoM.S. LebbéC. McArthurG. AsciertoP.A. DanielsG.A. LongG.V. BastholtL. RizzoJ.I. BaloghA. MoshykA. HodiF.S. WolchokJ.D. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N. Engl. J. Med.2019381161535154610.1056/NEJMoa191083631562797
     [Google Scholar]
  28. EggermontA.M.M. Chiarion-SileniV. GrobJ.J. DummerR. WolchokJ.D. SchmidtH. HamidO. RobertC. AsciertoP.A. RichardsJ.M. LebbéC. FerraresiV. SmylieM. WeberJ.S. MaioM. KontoC. HoosA. de PrilV. GurunathR.K. de SchaetzenG. SuciuS. TestoriA. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial.Lancet Oncol.201516552253010.1016/S1470‑2045(15)70122‑125840693
     [Google Scholar]
  29. WolchokJ.D. NeynsB. LinetteG. NegrierS. LutzkyJ. ThomasL. WaterfieldW. SchadendorfD. SmylieM. GuthrieT.Jr GrobJ.J. ChesneyJ. ChinK. ChenK. HoosA. O’DayS.J. LebbéC. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study.Lancet Oncol.201011215516410.1016/S1470‑2045(09)70334‑120004617
     [Google Scholar]
  30. CoensC. Phase III trial (EORTC 18071/CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health related quality of life (HRQoL) results.Lancet Oncol.201718339310.1016/S1470‑2045(17)30015‑328162999
     [Google Scholar]
  31. AsciertoP.A. Del VecchioM. RobertC. MackiewiczA. Chiarion-SileniV. AranceA. LebbéC. BastholtL. HamidO. RutkowskiP. McNeilC. GarbeC. LoquaiC. DrenoB. ThomasL. GrobJ.J. LiszkayG. NyakasM. GutzmerR. PikielJ. GrangeF. HoellerC. FerraresiV. SmylieM. SchadendorfD. MortierL. SvaneI.M. HennickenD. QureshiA. MaioM. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol.201718561162210.1016/S1470‑2045(17)30231‑028359784
     [Google Scholar]
  32. O’DayS.J. MaioM. Chiarion-SileniV. GajewskiT.F. PehambergerH. BondarenkoI.N. QueiroloP. LundgrenL. MikhailovS. RomanL. VerschraegenC. HumphreyR. IbrahimR. de PrilV. HoosA. WolchokJ.D. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study.Ann. Oncol.20102181712171710.1093/annonc/mdq01320147741
     [Google Scholar]
  33. WolchokJ.D. WeberJ.S. MaioM. NeynsB. HarmankayaK. ChinK. CykowskiL. de PrilV. HumphreyR. LebbéC. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.Ann. Oncol.20132482174218010.1093/annonc/mdt16123666915
     [Google Scholar]
  34. RobertC. LongG.V. BradyB. DutriauxC. MaioM. MortierL. HasselJ.C. RutkowskiP. McNeilC. Kalinka-WarzochaE. SavageK.J. HernbergM.M. LebbéC. CharlesJ. MihalcioiuC. Chiarion-SileniV. MauchC. CognettiF. AranceA. SchmidtH. SchadendorfD. GogasH. Lundgren-ErikssonL. HorakC. SharkeyB. WaxmanI.M. AtkinsonV. AsciertoP.A. Nivolumab in previously untreated melanoma without BRAF mutation.N. Engl. J. Med.2015372432033010.1056/NEJMoa141208225399552
     [Google Scholar]
  35. AsciertoP.A. LongG.V. RobertC. BradyB. DutriauxC. Di GiacomoA.M. MortierL. HasselJ.C. RutkowskiP. McNeilC. Kalinka-WarzochaE. SavageK.J. HernbergM.M. LebbéC. CharlesJ. MihalcioiuC. Chiarion-SileniV. MauchC. CognettiF. NyL. AranceA. SvaneI.M. SchadendorfD. GogasH. SaciA. JiangJ. RizzoJ. AtkinsonV. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial.JAMA Oncol.20195218719410.1001/jamaoncol.2018.451430422243
     [Google Scholar]
  36. RobertC. LongG.V. BradyB. DutriauxC. Di GiacomoA.M. MortierL. RutkowskiP. HasselJ.C. McNeilC.M. KalinkaE.A. LebbéC. CharlesJ. HernbergM.M. SavageK.J. Chiarion-SileniV. MihalcioiuC. MauchC. AranceA. CognettiF. NyL. SchmidtH. SchadendorfD. GogasH. ZocoJ. ReS. AsciertoP.A. AtkinsonV. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma.J. Clin. Oncol.202038333937394610.1200/JCO.20.0099532997575
     [Google Scholar]
  37. HodiF.S. Chiarion-SileniV. GonzalezR. GrobJ.J. RutkowskiP. CoweyC.L. LaoC.D. SchadendorfD. WagstaffJ. DummerR. FerrucciP.F. SmylieM. HillA. HoggD. Marquez-RodasI. JiangJ. RizzoJ. LarkinJ. WolchokJ.D. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.Lancet Oncol.201819111480149210.1016/S1470‑2045(18)30700‑930361170
     [Google Scholar]
  38. Weber, J.S.; Mandalà , M.; Vecchio, M.D.; Gogas, H.; Ana , M. Arance, Cowey, C.L.; Dalle , S. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). J.Clin.Oncol., 2018, 36, (Suppl.15) , 9502-9502.10.1200/JCO.2018.36.15_suppl.9502
  39. WeberJ. MandalaM. Del VecchioM. GogasH.J. AranceA.M. CoweyC.L. DalleS. SchenkerM. Chiarion-SileniV. Marquez-RodasI. GrobJ.J. ButlerM.O. MiddletonM.R. MaioM. AtkinsonV. QueiroloP. GonzalezR. KudchadkarR.R. SmylieM. MeyerN. MortierL. AtkinsM.B. LongG.V. BhatiaS. LebbéC. RutkowskiP. YokotaK. YamazakiN. KimT.M. de PrilV. SabaterJ. QureshiA. LarkinJ. AsciertoP.A. CheckMate 238 Collaborators Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.N. Engl. J. Med.2017377191824183510.1056/NEJMoa170903028891423
     [Google Scholar]
  40. WeberJ.S. Del VecchioM. MandalaM. GogasH. AranceA.M. DalleS. CoweyC.L. SchenkerM. GrobJ.J. Chiarion-SileniV. Marquez-RodasI. ButlerM.O. MaioM. MiddletonM.R. TangT. SaciA. De PrilV. LoboM. LarkinJ.M.G. AsciertoP.A. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial.Ann. Oncol.201930v533v53410.1093/annonc/mdz255
     [Google Scholar]
  41. LarkinJ. MinorD. D’AngeloS. NeynsB. SmylieM. MillerW.H.Jr GutzmerR. LinetteG. ChmielowskiB. LaoC.D. LoriganP. GrossmannK. HasselJ.C. SznolM. DaudA. SosmanJ. KhushalaniN. SchadendorfD. HoellerC. WalkerD. KongG. HorakC. WeberJ. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial.J. Clin. Oncol.201836438339010.1200/JCO.2016.71.802328671856
     [Google Scholar]
  42. WeberJ.S. D’AngeloS.P. MinorD. HodiF.S. GutzmerR. NeynsB. HoellerC. KhushalaniN.I. MillerW.H.Jr LaoC.D. LinetteG.P. ThomasL. LoriganP. GrossmannK.F. HasselJ.C. MaioM. SznolM. AsciertoP.A. MohrP. ChmielowskiB. BryceA. SvaneI.M. GrobJ.J. KrackhardtA.M. HorakC. LambertA. YangA.S. LarkinJ. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.Lancet Oncol.201516437538410.1016/S1470‑2045(15)70076‑825795410
     [Google Scholar]
  43. SchadendorfD. AsciertoP.A. HaanenJ. EspinosaE. DemidovL. GarbeC. GuidaM. LoriganP. Chiarion-SileniV. GogasH. MaioM. FierroM.T. HoellerC. TerheydenP. GutzmerR. GurenT.K. BafaloukosD. RutkowskiP. PlummerR. WaterstonA. KaatzM. MandalaM. Marquez-RodasI. Muñoz-CouseloE. DummerR. GrigoryevaE. YoungT.C. NathanP. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).Eur. J. Cancer201912114415310.1016/j.ejca.2019.08.01431581055
     [Google Scholar]
  44. SchadendorfD. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).Endocrine201791560
     [Google Scholar]
  45. NathanP. AsciertoP.A. HaanenJ. EspinosaE. DemidovL. GarbeC. GuidaM. LoriganP. Chiarion-SileniV. GogasH. MaioM. FierroM.T. HoellerC. TerheydenP. GutzmerR. GurenT.K. BafaloukosD. RutkowskiP. PlummerR. WaterstonA. KaatzM. MandalaM. Marquez-RodasI. Muñoz-CouseloE. DummerR. GrigoryevaE. YoungT.C. SchadendorfD. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).Eur. J. Cancer201911916817810.1016/j.ejca.2019.07.01031445199
     [Google Scholar]
  46. WeberJ. GibneyG. KudchadkarR. YuB. ChengP. MartinezA.J. KroegerJ. RichardsA. McCormickL. MobergV. CroninH. ZhaoX. SchellM. ChenY.A. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab.Cancer Immunol. Res.20164434535310.1158/2326‑6066.CIR‑15‑019326873574
     [Google Scholar]
  47. WeberJ.S. GibneyG. SullivanR.J. SosmanJ.A. SlingluffC.L.Jr LawrenceD.P. LoganT.F. SchuchterL.M. NairS. FecherL. BuchbinderE.I. BerghornE. RuisiM. KongG. JiangJ. HorakC. HodiF.S. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial.Lancet Oncol.201617794395510.1016/S1470‑2045(16)30126‑727269740
     [Google Scholar]
  48. MortezaeeK. MajidpoorJ. NajafiS. TasaD. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies.Biomed. Pharmacother.202315811415010.1016/j.biopha.2022.11415036577330
     [Google Scholar]
  49. HodiF.S. ChesneyJ. PavlickA.C. RobertC. GrossmannK.F. McDermottD.F. LinetteG.P. MeyerN. GiguereJ.K. AgarwalaS.S. ShaheenM. ErnstoffM.S. MinorD.R. SalamaA.K. TaylorM.H. OttP.A. HorakC. GagnierP. JiangJ. WolchokJ.D. PostowM.A. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Lancet Oncol.201617111558156810.1016/S1470‑2045(16)30366‑727622997
     [Google Scholar]
  50. NamikawaK. KiyoharaY. TakenouchiT. UharaH. UchiH. YoshikawaS. TakatsukaS. KogaH. WadaN. MinamiH. HatsumichiM. AsadaS. NambaY. YamazakiN. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.Eur. J. Cancer201810511412610.1016/j.ejca.2018.09.02530447539
     [Google Scholar]
  51. WolchokJ.D. KlugerH. CallahanM.K. PostowM.A. RizviN.A. LesokhinA.M. SegalN.H. AriyanC.E. GordonR.A. ReedK. BurkeM.M. CaldwellA. KronenbergS.A. AgunwambaB.U. ZhangX. LowyI. InzunzaH.D. FeelyW. HorakC.E. HongQ. KormanA.J. WiggintonJ.M. GuptaA. SznolM. Nivolumab plus ipilimumab in advanced melanoma.N. Engl. J. Med.2013369212213310.1056/NEJMoa130236923724867
     [Google Scholar]
  52. PostowM.A. ChesneyJ. PavlickA.C. RobertC. GrossmannK. McDermottD. LinetteG.P. MeyerN. GiguereJ.K. AgarwalaS.S. ShaheenM. ErnstoffM.S. MinorD. SalamaA.K. TaylorM. OttP.A. RollinL.M. HorakC. GagnierP. WolchokJ.D. HodiF.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N. Engl. J. Med.2015372212006201710.1056/NEJMoa141442825891304
     [Google Scholar]
  53. ZimmerL. ApuriS. ErogluZ. KottschadeL.A. ForschnerA. GutzmerR. SchlaakM. HeinzerlingL. KrackhardtA.M. LoquaiC. MarkovicS.N. JosephR.W. MarkeyK. UtikalJ.S. WeishauptC. GoldingerS.M. SondakV.K. ZagerJ.S. SchadendorfD. KhushalaniN.I. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.Eur. J. Cancer201775475510.1016/j.ejca.2017.01.00928214657
     [Google Scholar]
  54. TawbiH.A. ForsythP.A. AlgaziA. HamidO. HodiF.S. MoschosS.J. KhushalaniN.I. LewisK. LaoC.D. PostowM.A. AtkinsM.B. ErnstoffM.S. ReardonD.A. PuzanovI. KudchadkarR.R. ThomasR.P. TarhiniA. PavlickA.C. JiangJ. AvilaA. DemeloS. MargolinK. Nivolumab and ipilimumab in melanoma metastatic to the brain.N. Engl. J. Med.2018379872273010.1056/NEJMoa180545330485776
     [Google Scholar]
  55. LongG.V. AtkinsonV. LoS. SandhuS. GuminskiA.D. BrownM.P. WilmottJ.S. EdwardsJ. GonzalezM. ScolyerR.A. MenziesA.M. McArthurG.A. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study.Lancet Oncol.201819567268110.1016/S1470‑2045(18)30139‑629602646
     [Google Scholar]
  56. BlankC.U. RozemanE.A. FanchiL.F. SikorskaK. van de WielB. KvistborgP. KrijgsmanO. van den BraberM. PhilipsD. BroeksA. van ThienenJ.V. MalloH.A. AdriaanszS. ter MeulenS. PronkL.M. Grijpink-OngeringL.G. BruiningA. GittelmanR.M. WarrenS. van TinterenH. PeeperD.S. HaanenJ.B.A.G. van AkkooiA.C.J. SchumacherT.N. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.Nat. Med.201824111655166110.1038/s41591‑018‑0198‑030297911
     [Google Scholar]
  57. SchadendorfD. WolchokJ.D. HodiF.S. Chiarion-SileniV. GonzalezR. RutkowskiP. GrobJ.J. CoweyC.L. LaoC.D. ChesneyJ. RobertC. GrossmannK. McDermottD. WalkerD. BhoreR. LarkinJ. PostowM.A. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials.J. Clin. Oncol.201735343807381410.1200/JCO.2017.73.228928841387
     [Google Scholar]
  58. Hodi, F.; Stephen.; Postow, M.A.; Chesney, J.A .; Anna ,C.; Pavlick.; Robert,C.; Kenneth , F.; Grossmann, David , F.; McDermott. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). J.Clin.Oncol., 2016, 34(suppl.15) , 9518-9518.10.1200/JCO.2016.34.15_suppl.9518
  59. TopalianS.L. SznolM. McDermottD.F. KlugerH.M. CarvajalR.D. SharfmanW.H. BrahmerJ.R. LawrenceD.P. AtkinsM.B. PowderlyJ.D. LemingP.D. LipsonE.J. PuzanovI. SmithD.C. TaubeJ.M. WiggintonJ.M. KolliaG.D. GuptaA. PardollD.M. SosmanJ.A. HodiF.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J. Clin. Oncol.201432101020103010.1200/JCO.2013.53.010524590637
     [Google Scholar]
  60. HaywardN.K. WilmottJ.S. WaddellN. JohanssonP.A. FieldM.A. NonesK. PatchA.M. KakavandH. AlexandrovL.B. BurkeH. JakrotV. KazakoffS. HolmesO. LeonardC. SabarinathanR. MularoniL. WoodS. XuQ. WaddellN. TembeV. PupoG.M. De Paoli-IseppiR. VilainR.E. ShangP. LauL.M.S. DaggR.A. SchrammS.J. PritchardA. Dutton-RegesterK. NewellF. FitzgeraldA. ShangC.A. GrimmondS.M. PickettH.A. YangJ.Y. StretchJ.R. BehrenA. KeffordR.F. HerseyP. LongG.V. CebonJ. ShackletonM. SpillaneA.J. SawR.P.M. López-BigasN. PearsonJ.V. ThompsonJ.F. ScolyerR.A. MannG.J. Whole-genome landscapes of major melanoma subtypes.Nature2017545765317518010.1038/nature2207128467829
     [Google Scholar]
  61. RiazN. Tumor and microenvironment evolution during immunotherapy with nivolumab.Cell2017171493494910.1016/j.cell.2017.09.028
     [Google Scholar]
  62. LarkinJ. Chiarion-SileniV. GonzalezR. GrobJ.J. CoweyC.L. LaoC.D. SchadendorfD. DummerR. SmylieM. RutkowskiP. FerrucciP.F. HillA. WagstaffJ. CarlinoM.S. HaanenJ.B. MaioM. Marquez-RodasI. McArthurG.A. AsciertoP.A. LongG.V. CallahanM.K. PostowM.A. GrossmannK. SznolM. DrenoB. BastholtL. YangA. RollinL.M. HorakC. HodiF.S. WolchokJ.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N. Engl. J. Med.20153731233410.1056/NEJMoa150403026027431
     [Google Scholar]
  63. CurranM.A. MontalvoW. YagitaH. AllisonJ.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc. Natl. Acad. Sci. USA201010794275428010.1073/pnas.091517410720160101
     [Google Scholar]
  64. Freeman-KellerM. KimY. CroninH. RichardsA. GibneyG. WeberJ.S. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes.Clin. Cancer Res.201622488689410.1158/1078‑0432.CCR‑15‑113626446948
     [Google Scholar]
  65. RozemanE.A. MenziesA.M. van AkkooiA.C.J. AdhikariC. BiermanC. van de WielB.A. ScolyerR.A. KrijgsmanO. SikorskaK. ErikssonH. BroeksA. van ThienenJ.V. GuminskiA.D. AcostaA.T. ter MeulenS. KoenenA.M. BoschL.J.W. ShannonK. PronkL.M. GonzalezM. Ch’ngS. Grijpink-OngeringL.G. StretchJ. HeijminkS. van TinterenH. HaanenJ.B.A.G. NiewegO.E. KlopW.M.C. ZuurC.L. SawR.P.M. van HoudtW.J. PeeperD.S. SpillaneA.J. HanssonJ. SchumacherT.N. LongG.V. BlankC.U. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial.Lancet Oncol.201920794896010.1016/S1470‑2045(19)30151‑231160251
     [Google Scholar]
  66. LebbéC. MeyerN. MortierL. Marquez-RodasI. RobertC. RutkowskiP. MenziesA.M. EigentlerT. AsciertoP.A. SmylieM. SchadendorfD. AjazM. SvaneI.M. GonzalezR. RollinL. Lord-BessenJ. SaciA. GrigoryevaE. PigozzoJ. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 trial.J. Clin. Oncol.2019371186787510.1200/JCO.18.0199830811280
     [Google Scholar]
  67. ShoushtariA.N. FriedmanC.F. Navid-AzarbaijaniP. PostowM.A. CallahanM.K. MomtazP. PanageasK.S. WolchokJ.D. ChapmanP.B. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma.JAMA Oncol.2018419810110.1001/jamaoncol.2017.239128817755
     [Google Scholar]
  68. ChengP. ChenX. DaltonR. CalescibettaA. SoT. GilvaryD. WardG. SmithV. EckardS. FoxJ.A. GuenotJ. MarkowitzJ. ClevelandJ.L. WrightK.L. ListA.F. WeiS. EksiogluE.A. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.Mol. Ther.20223062315232610.1016/j.ymthe.2022.02.00535150889
     [Google Scholar]
  69. Sade-Feldman, M.; Kanterman, J.; Klieger, Y.; Ish-Shalom, E.; Olga, M.; Saragovi, A.; Shtainberg, H.; Lotem, M.; Baniyash, M. Clinical significance of circulating CD33+ CD11b+ HLA-DR− myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clinical Cancer Research, 2016, 22(23), 5661-567210.1158/1078‑0432.CCR‑15‑310427178742
  70. PizzurroG.A. BridgesK. KaechS. BosenbergM. Miller-JensenK. Abstract B48: CD40-agonist treatment can prime the inflammatory response of macrophages and reverse checkpoint inhibitor resistance in melanoma.Cancer Immunol. Res.20221012_SupplementB48B4810.1158/2326‑6074.TUMIMM22‑B48
     [Google Scholar]
  71. MortezaeeK. B7-H3 immunoregulatory roles in cancer.Biomed. Pharmacother.202316311489010.1016/j.biopha.2023.11489037196544
     [Google Scholar]
  72. BaughmanJ. LooD. ChenF. MooreP. BonviniE. VasselliJ. WiggintonJ. CohenR. A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer.J. Immunother. Cancer201532Suppl. 2P17710.1186/2051‑1426‑3‑S2‑P177
     [Google Scholar]
  73. MortezaeeK. B7x in cancer immunity and immunotherapy.Int. Immunopharmacol.202311811013310.1016/j.intimp.2023.11013337028278
     [Google Scholar]
  74. MortezaeeK. HHLA2 immune-regulatory roles in cancer.Biomed. Pharmacother.202316211463910.1016/j.biopha.2023.11463937011487
     [Google Scholar]
  75. HuangF. WuJ. ChengX. WangJ. WenX. LiJ. ZhangQ. JiangH. DingQ. ZhuX. ZhangX. DingY. LiD. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.Front. Immunol.20221390216710.3389/fimmu.2022.90216736003385
     [Google Scholar]
  76. ChenF. XuY. ChenY. ShanS. TIGIT enhances CD4 + regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model.Cancer Med.20209103584359110.1002/cam4.297632212317
     [Google Scholar]
  77. ZhouX. DingX. LiH. YangC. MaZ. XuG. YangS. ZhangD. XieX. XinL. LuoX. Upregulation of TIGIT and PD-1 in colorectal cancer with mismatch-repair deficiency.Immunol. Invest.202150433835510.1080/08820139.2020.175813032397769
     [Google Scholar]
  78. FourcadeJ. SunZ. ChauvinJ.M. KaM. DavarD. PaglianoO. WangH. SaadaS. MennaC. AminR. SanderC. KirkwoodJ.M. KormanA.J. ZarourH.M. CD226 opposes TIGIT to disrupt Tregs in melanoma.JCI Insight201831412115710.1172/jci.insight.12115730046006
     [Google Scholar]
  79. LepletierA. MadoreJ. O’DonnellJ.S. JohnstonR.L. LiX.Y. McDonaldE. AhernE. KuchelA. EastgateM. PearsonS.A. MallardoD. AsciertoP.A. MassiD. MerelliB. MandalaM. WilmottJ.S. MenziesA.M. LeducC. StaggJ. RoutyB. LongG.V. ScolyerR.A. BaldT. WaddellN. DougallW.C. TengM.W.L. SmythM.J. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma.Clin. Cancer Res.202026143671368110.1158/1078‑0432.CCR‑19‑392532345648
     [Google Scholar]
  80. KawashimaS. InozumeT. KawazuM. UenoT. NagasakiJ. TanjiE. HonobeA. OhnumaT. KawamuraT. UmedaY. NakamuraY. KawasakiT. KiniwaY. YamasakiO. FukushimaS. IkeharaY. ManoH. SuzukiY. NishikawaH. MatsueH. TogashiY. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.J. Immunother. Cancer202291100313410.1136/jitc‑2021‑00313434795004
     [Google Scholar]
  81. DummerR. RobertC. ScolyerR.A. TaubeJ.M. TetzlaffM.T. HillA. GrobJ-J. PortnoyD.C. LebbeC. KhattakM.A. CohenJ. Bar-SelaG. MehmiI. FrommerR.S. MeyerN. RenY. Fukunaga-KalabisM. KreplerC. LongG.V. Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma.Cancer Res.2023838_SupplCT002CT00210.1158/1538‑7445.AM2023‑CT002
     [Google Scholar]
  82. HedvatC.V. LeeG. BaxiV. DziubaK. LockeD. LiB. EdwardsR. Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors.Ann. Oncol.201930v80910.1093/annonc/mdz269.039
     [Google Scholar]
  83. ZhaoW. Galectin-3 mediates tumor cell–stroma interactions by activating pancreatic stellate cells to produce cytokines via integrin signaling.Gastroenterology201815451524153710.1053/j.gastro.2017.12.014
     [Google Scholar]
  84. YiW. QiaoT. YangZ. HuL. SunM. FanH. XuY. LvZ. The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis.Mater. Today Bio20221710047010.1016/j.mtbio.2022.10047036345363
     [Google Scholar]
  85. SinghL. SinghM.K. KumarN. JhaJ. LomiN. SenS. KashyapS. 189P Prognostic significance of lymphocyte activation gene-3 (LAG3 gene) in uveal melanoma patients.Ann. Oncol.202132S1463S146410.1016/j.annonc.2021.10.209
     [Google Scholar]
  86. HuuhtanenJ. KasanenH. PeltolaK. LönnbergT. GlumoffV. BrückO. DufvaO. PeltonenK. VikkulaJ. JokinenE. IlanderM. LeeM.H. MäkeläS. NyakasM. LiB. HernbergM. BonoP. LähdesmäkiH. KreutzmanA. MustjokiS. Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma.J. Clin. Invest.20231336e16480910.1172/JCI16480936719749
     [Google Scholar]
  87. AsciertoP.A. BonoP. BhatiaS. MeleroI. NyakasM.S. SvaneI-M. LarkinJ. Gomez-RocaC. SchadendorfD. DummerR. MarabelleA. HoellerC. MaurerM. HarbisonC.T. MitraP. SuryawanshiS. ThudiumK. Muñoz CouseloE. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations.Ann. Oncol.201728v611v61210.1093/annonc/mdx440.011
     [Google Scholar]
  88. AmariaR.N. PostowM. BurtonE.M. TetzlaffM.T. RossM.I. Torres-CabalaC. GlitzaI.C. DuanF. MiltonD.R. BusamK. SimpsonL. McQuadeJ.L. WongM.K. GershenwaldJ.E. LeeJ.E. GoepfertR.P. KeungE.Z. FisherS.B. Betof-WarnerA. ShoushtariA.N. CallahanM. CoitD. BartlettE.K. BelloD. MomtazP. NicholasC. GuA. ZhangX. KoriviB.R. PatnanaM. PatelS.P. DiabA. LucciA. PrietoV.G. DaviesM.A. AllisonJ.P. SharmaP. WargoJ.A. AriyanC. TawbiH.A. Neoadjuvant relatlimab and nivolumab in resectable melanoma.Nature2022611793415516010.1038/s41586‑022‑05368‑836289334
     [Google Scholar]
  89. TawbiH.A. SchadendorfD. LipsonE.J. AsciertoP.A. MatamalaL. Castillo GutiérrezE. RutkowskiP. GogasH.J. LaoC.D. De MenezesJ.J. DalleS. AranceA. GrobJ.J. SrivastavaS. AbaskharounM. HamiltonM. KeidelS. SimonsenK.L. SobieskA.M. LiB. HodiF.S. LongG.V. RELATIVITY-047 Investigators Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N. Engl. J. Med.20223861243410.1056/NEJMoa210997034986285
     [Google Scholar]
  90. SpeeckaertR. VermaelenK. van GeelN. AutierP. LambertJ. HaspeslaghM. van GeleM. ThielemansK. NeynsB. RocheN. VerbekeN. DeronP. SpeeckaertM. BrochezL. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.Eur. J. Cancer201248132004201110.1016/j.ejca.2011.09.00722033321
     [Google Scholar]
  91. GibneyG. HamidO. LutzkyJ. OlszanskiA. GangadharT. GajewskiT. ChmielowskiB. HanksB. BoasbergP. ZhaoY. NewtonR. BowmanJ. MaleskiJ. LeopoldL. WeberJ.S. 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma.Eur. J. Cancer20155151S106S10710.1016/S0959‑8049(16)30312‑4
     [Google Scholar]
  92. KjeldsenJ. LorentzenL. CathrineH. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.Nat. Med.202127122212222310.1038/s41591‑021‑01544‑x34887574
     [Google Scholar]
  93. ChangH. WenX. LiZ. LingZ. ZhengY. XuC. Co-delivery of dendritic cell vaccine and anti-PD-1 antibody with cryomicroneedles for combinational immunotherapy.Bioeng. Transl. Med.202385e1045710.1002/btm2.1045737693072
     [Google Scholar]
  94. NajafiS. MortezaeeK. Advances in dendritic cell vaccination therapy of cancer.Biomed. Pharmacother.202316411495410.1016/j.biopha.2023.11495437257227
     [Google Scholar]
  95. WilgenhofS. CorthalsJ. HeirmanC. van BarenN. LucasS. KvistborgP. ThielemansK. NeynsB. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma.J. Clin. Oncol.201634121330133810.1200/JCO.2015.63.412126926680
     [Google Scholar]
  96. RibasA. Comin-AnduixB. ChmielowskiB. JalilJ. de la RochaP. McCannelT.A. OchoaM.T. SejaE. VillanuevaA. OsegueraD.K. StraatsmaB.R. CochranA.J. GlaspyJ.A. HuiL. MarincolaF.M. WangE. EconomouJ.S. Gomez-NavarroJ. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.Clin. Cancer Res.200915196267627610.1158/1078‑0432.CCR‑09‑125419789309
     [Google Scholar]
  97. GoradelN.H. MohajelN. MalekshahiZ.V. JahangiriS. NajafiM. FarhoodB. MortezaeeK. NegahdariB. ArashkiaA. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.J. Cell. Physiol.201923468636864610.1002/jcp.2785030515798
     [Google Scholar]
  98. WeiX. WangX. BaiX. LiC. MaoL. ChiZ. LianB. BixiaT. KongY. DaiJ. AndtbackaR.H.I. GuoJ. CuiC-L. SiL. 795P A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma.Ann. Oncol.202233S90710.1016/j.annonc.2022.07.921
     [Google Scholar]
  99. SilkA.W. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.Cancer Immunol. Immunother.20237261405141510.1007/s00262‑022‑03314‑136445410
     [Google Scholar]
  100. MortezaeeK. MajidpoorJ. FathiF. Extracellular vesicle isolation, purification and evaluation in cancer diagnosis.Expert Rev. Mol. Med.202224e4110.1017/erm.2022.3436268744
     [Google Scholar]
  101. LiuN. ZhangJ. YinM. LiuH. ZhangX. LiJ. YanB. GuoY. ZhouJ. TaoJ. HuS. ChenX. PengC. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.Mol. Ther.20212972321233410.1016/j.ymthe.2021.03.01333744468
     [Google Scholar]
  102. LiJ. LiJ. PengY. DuY. YangZ. QiX. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies.J. Control. Release202335342343310.1016/j.jconrel.2022.11.05336470333
     [Google Scholar]
  103. VeermanR.E. Antigen-loaded extracellular vesicles induce responsiveness to anti-pd-1 and anti-pd-l1 treatment in a checkpoint refractory melanoma model.Cancer Immunol. Res.202311221722710.1158/2326‑6066.CIR‑22‑054036546872
     [Google Scholar]
  104. NaeemP. Anticarcinogenic impact of extracellular vesicles (exosomes) from cord blood stem cells in malignant melanoma: A potential biological treatment.J. Cell. Mol. Med.202327222223110.1111/jcmm.1763936545841
     [Google Scholar]
  105. JungD. ShinS. KangS.M. JungI. RyuS. NohS. ChoiS.J. JeongJ. LeeB.Y. KimK.S. KimC.S. YoonJ.H. LeeC.H. BucherF. KimY.N. ImS.H. SongB.J. YeaK. BaekM.C. Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery.J. Extracell. Vesicles202211121228710.1002/jev2.1228736447429
     [Google Scholar]
  106. Matson, V.; Fessler, J.; Bao, R.; Chongsuwat, T.; Zha, Y.; Alegre, M. L.; & Gajewski, T. F. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science., 2018, 359(6371), 104-10810.1126/science.aao329029302014
  107. McCullochJ.A. DavarD. RodriguesR.R. BadgerJ.H. FangJ.R. ColeA.M. BalajiA.K. VetizouM. PrescottS.M. FernandesM.R. CostaR.G.F. YuanW. SalcedoR. BahadirogluE. RoyS. DeBlasioR.N. MorrisonR.M. ChauvinJ.M. DingQ. ZidiB. LowinA. ChakkaS. GaoW. PaglianoO. ErnstS.J. RoseA. NewmanN.K. MorgunA. ZarourH.M. TrinchieriG. DzutsevA.K. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.Nat. Med.202228354555610.1038/s41591‑022‑01698‑235228752
     [Google Scholar]
  108. PietrzakB. TomelaK. Olejnik-SchmidtA. GalusŁ. MackiewiczJ. KaczmarekM. MackiewiczA. SchmidtM. A clinical outcome of the anti-PD-1 therapy of melanoma in polish patients is mediated by population-specific gut microbiome composition.Cancers20221421536910.3390/cancers1421536936358789
     [Google Scholar]
  109. Nyelia, W.; Hoyd, R.; Caroline , E.; Wheeler, Lynn, M.; Bibi, A.; Gray, S.; Bodner , M. The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma. J.Clin.Oncol., 2022, 40 (Suppl.16), 9568-9568.10.1200/JCO.2022.40.16_suppl.9568
  110. BaruchE.N. YoungsterI. Ben-BetzalelG. OrtenbergR. LahatA. KatzL. AdlerK. Dick-NeculaD. RaskinS. BlochN. RotinD. AnafiL. AviviC. MelnichenkoJ. Steinberg-SilmanY. MamtaniR. HaratiH. AsherN. Shapira-FrommerR. Brosh-NissimovT. EshetY. Ben-SimonS. ZivO. KhanM.A.W. AmitM. AjamiN.J. BarshackI. SchachterJ. WargoJ.A. KorenO. MarkelG. BoursiB. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science2021371652960260910.1126/science.abb592033303685
     [Google Scholar]
  111. Routy, Bertrand, Lenehan, J.; Daisley, B.; Messaoudene, M.; Al, K.; Richard, C.; Miller, W. 614 microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients. J.Immune.Ther.Cancer., 2022, 10 (Suppl.2).10.1136/jitc‑2022‑SITC2022.0614
  112. DavarD. DzutsevA.K. McCullochJ.A. RodriguesR.R. ChauvinJ.M. MorrisonR.M. DeblasioR.N. MennaC. DingQ. PaglianoO. ZidiB. ZhangS. BadgerJ.H. VetizouM. ColeA.M. FernandesM.R. PrescottS. CostaR.G.F. BalajiA.K. MorgunA. Vujkovic-CvijinI. WangH. BorhaniA.A. SchwartzM.B. DubnerH.M. ErnstS.J. RoseA. NajjarY.G. BelkaidY. KirkwoodJ.M. TrinchieriG. ZarourH.M. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients.Science2021371652959560210.1126/science.abf336333542131
     [Google Scholar]
  113. Pelster, Meredith, Stephen , K.; Gruschkus, Bassett,R.; Dan ,S.; Gombos, Shephard,M.; Posada, L.; Glover, M .;Diab, A.;Hwu, P.; Patel , S. Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). J. Exp. Med., 2019,207 (10), 9522-9522.10.1200/JCO.2019.37.15_suppl.9522
  114. FourcadeJ. SunZ. BenallaouaM. GuillaumeP. LuescherI.F. SanderC. KirkwoodJ.M. KuchrooV. ZarourH.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients.J. Exp. Med.2010207102175218610.1084/jem.2010063720819923
     [Google Scholar]
  115. LiedeA. HernandezR.K. WadeS.W. BoR. NussbaumN.C. AhernE. DougallW.C. SmythM.J. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.OncoImmunology2018712148030110.1080/2162402X.2018.148030130524886
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673283943240227104122
Loading
Immunotherapy of Human Melanoma: Past, Present, Future
Curr. Med. Chem. 32, 3548 (2025); https://doi.org/10.2174/0109298673283943240227104122
/content/journals/cmc/10.2174/0109298673283943240227104122
/content/journals/cmc/10.2174/0109298673283943240227104122
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adverse event (AE); melanoma; Nivolumab; oncolytic viruses; programmed death-1 (PD-1); programmed death-ligand 1 (PD-L1)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test